Abstract: Objective To investigate the role of preoperative systemic immune inflammation index (SII) in the prognosis of hepatocellular carcinoma (HCC) treated with transcatheter arterial chemoembolization (TACE). Methods The clinical data of 127 patients with HCC who underwent TACE in the Baise people’s hospital from January 2017 to October 2021 were analyzed retrospectively. We determine the predictive value of SII by calculating SII value and making receiver operating characteristic (ROC) curve. Results The area under curve (AUC) of SII calculated by ROC curve was 0.707, the corresponding optimal cut-off value was 337.125. With this value as the boundary, the SII was defined as low SII group and high SII group. The 1-year and 2-year survival rates of low SII group were 67.4% and 51.1%, while those in high SII group were 35.4% and 20.2%. The median values of low SII group and high SII group were 36.0 months and 9.0 months, respectively. The survival rate of low SII group revealed a better prognosis. Conclusion A higher level of SII before surgery may be a risk factor for poor prognosis of HCC, and the survival rate of patients with lower SII level is better than those of patients with higher SII level.

Key words: Hepatocellular carcinoma, Survival analysis, Hepatic artery chemoembolization, Systemic immune inflammatory index